FDA Brief

Warning letters Drugs

FDA warning letter to

Peaks Curative, LLC dba Peaks

LowIssued Feb 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

FDA warned Peaks Curative over false or misleading website claims for compounded (pharmacy-made) semaglutide, including implied FDA approval.

What happened

In December 2025, FDA reviewed https://peakscurative.com and found it offered compounded drug products, including semaglutide. FDA said the site’s label image showed “Peak Now,” suggesting Peak Now made the drugs when FDA says it did not, and the site claimed the products were FDA-approved, clinically proven, and safe and effective. FDA said compounded drugs are not FDA-approved, so these claims are false or misleading (misbranding).

What FDA found

  1. The website label image names “Peak Now” as if it were the compounder, but FDA says it is not.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; 21 CFR § 201.1(h)(2)
  2. The website says compounded semaglutide is an “FDA-approved treatment,” but compounded drugs are not FDA-approved.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. The website says the product is “clinically proven” for weight loss, which FDA treats as misleading for these compounded products.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  4. The website calls the products “safe, affordable, and effective,” which FDA treats as false or misleading.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  5. The website says the compounded products use FDA-approved active ingredients, which FDA says implies the compounded products themselves were FDA-approved or evaluated.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  6. FDA says the misbranded products were introduced or delivered for introduction into interstate commerce.

    FDCA § 301(a) [21 U.S.C. § 331(a)]

What FDA wants

Within 15 working days, Peaks must respond to FDA’s Office of Compounding Quality and Compliance describing steps taken to address the violations and prevent recurrence. FDA asks Peaks to identify the entities that produce the products, provide sample labeling, and address or modify/remove the misleading website claims.

Who should pay attention

  • telehealth companies selling compounded semaglutide
  • compounding pharmacies or outsourcing facilities whose drugs are marketed by telehealth sites
  • marketers and websites making FDA-approval claims for compounded drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low